Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.75 Analyst target: $7.50 Upside: 328.57%
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. The company is headquartered in Paramus, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.